NUCALA DIN 02530821
Status: Marketed
Holder: GLAXOSMITHKLINE INC
Available to quote
Health Canada record
| Active ingredient(s) | MEPOLIZUMAB 40 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | R03DX09 MEPOLIZUMAB |
|---|
| Original market date | 13-Feb-2023 |
|---|
| Current status date | 13-Feb-2023 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MEPOLIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02492989 | NUCALA | GLAXOSMITHKLINE INC | Solution | MEPOLIZUMAB 100 MG | Marketed |
| 02492997 | NUCALA | GLAXOSMITHKLINE INC | Solution | MEPOLIZUMAB 100 MG | Marketed |
| 02449781 | NUCALA | GLAXOSMITHKLINE INC | Powder For Solution | MEPOLIZUMAB 100 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 29007 | 2022-09-15 | Supplement to a New Drug Submission (SNDS) | New presentation |
Request a quote for NUCALA
How to read a Canadian DIN record